Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mirac Özen"'
Autor:
Murat Bardakci, Hilal Karakas, Dogan Bayram, Nilufer Avci, Sait Kitapli, Mirac Ozen, Ferit Aslan, Caglar Koseoglu, Ahmet Kadioglu, Ilknur D. Onur, Teoman Sakalar, Mahmut Buyuksimsek, Ali Alkan, Yakup Ergun, Ali O. Kaya, Burak Bilgin, Bulent Yalcin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 p
Externí odkaz:
https://doaj.org/article/026e682bc12d48feb5f956194dcd0fe4
Autor:
Fatih Gürler, Fatih Tay, Zehra Sucuoğlu İşleyen, Tahir Yerlikaya, Engin Hendem, Selin Aktürk Esen, Osman Sütçüoğlu, Deniz Işık, Büşra Niğdelioğlu, Miraç Özen, Elif Şahin, Teoman Şakalar, Nilay Şengül Samancı, Özkan Alan, İlhan Hacıbekiroğlu, Efnan Algın, Melek Karakurt Yılmaz, Hacı Mehmet Türk, Berna Öksüzoğlu, Aydın Yavuz, Osman Yüksel, Hüseyin Bora, Ozan Yazıcı, Ahmet Özet, Nuriye Özdemir
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Neoadjuvant treatment is the standard treatment in locally advanced ESCC. However, the optimal chemotherapy regimen is not known. Method This is a retrospective observational cohort study conducted with propensity score matching.
Externí odkaz:
https://doaj.org/article/0c2407cd5a0448378847928577fc42af
Autor:
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In rea
Externí odkaz:
https://doaj.org/article/7d19cca4236d429b8424cc6bef6070f5
Autor:
Elif Şenocak Taşçi, Basak Oyan, Ozlem Sonmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Irem Oner, Havva Yesil Cinkir, Melek Karakurt Eryılmaz, Onur Yazdan Balçık, Nail Paksoy, Derya Kivrak Salim, Mirac Özen, Melike Ozcelik, Ali Arican, Ali Inal, Baran Akagunduz, Dinçer Aydın, Leyla Ozer, Nazim Serdar Turhal, Ahmet Gulmez
Publikováno v:
Journal of Clinical Oncology. 40:202-202
202 Background: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib (Reg) revealed promising results by improving overall survival compared to best supportive care. However, in real-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53bafb1d3de0a410579a00fc45d7f57e
https://doi.org/10.1200/jco.2022.40.4_suppl.202
https://doi.org/10.1200/jco.2022.40.4_suppl.202
Autor:
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/3738f873f38f42ca820c7d9a886f1eba
Autor:
Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç, Sercan Ön, Abdussamet Çelebi, Bengü Dursun, Ömer Acar, Seda Kahraman, Musa Barış Aykan, Ömür Kaman, Akif Doğan, Atike Pınar Erdoğan, Özde Melisa Celayir, Damla Günenç, Deniz Can Güven, İbrahim Vedat Bayoğlu, Tuğba Yavuzşen, İlhan Hacıbekiroğlu, Mevlüde İnanç, Saadettin Kılıçkap, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Breast, Vol 66, Iss , Pp 85-88 (2022)
Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), h
Externí odkaz:
https://doaj.org/article/18da86563ce64050a659105850fa47be
Autor:
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin, Denizcan Güven, Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan, Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker, Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç, Abdullah Sakin, Haci Mehmet Türk, Dilek Çağlayan, Şener Cihan, Yusuf Açikgöz, Doğan Uncu
Publikováno v:
Biomolecules & Biomedicine, Vol 22, Iss 5 (2022)
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred.
Externí odkaz:
https://doaj.org/article/76c42bc31695447ca49b70652deb5b62